1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
about
Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative updateAnalysis of bacterial biofilms using NMR-based metabolomicsMetabolomics of human brain aging and age-related neurodegenerative diseasesModulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosisMonitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinicThe 1H NMR profile of healthy dog cerebrospinal fluid.1H NMR Analysis of Cerebrospinal Fluid from Alzheimer's Disease Patients: An Example of a Possible Misinterpretation Due to Non-Adjustment of pHDisease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS.Mechanisms, models and biomarkers in amyotrophic lateral sclerosisQuantifying disease progression in amyotrophic lateral sclerosis.Gene expression changes in spinal motoneurons of the SOD1(G93A) transgenic model for ALS after treatment with G-CSF.The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosisMetabolomics of cerebrospinal fluid from humans treated for rabies.Biomarker Discovery and Translation in Metabolomics.Application of (1)h NMR spectroscopy-based metabolomics to sera of tuberculosis patients.Defective cholesterol metabolism in amyotrophic lateral sclerosis.A plural role for lipids in motor neuron diseases: energy, signaling and structure.Recent advances in metabolomics in neurological disease, and future perspectives.NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis.Advances in cellular models to explore the pathophysiology of amyotrophic lateral sclerosis.MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis.Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach.Metabolomics in amyotrophic lateral sclerosis: how far can it take us?Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis.MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis.Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders?Biochemical alterations associated with ALS.Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression.Metabolomics As a Tool for the Characterization of Drug-Resistant Epilepsy.Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthaseThallium stimulates ethanol production in immortalized hippocampal neurons.Neuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease.Metabolomics toward personalized medicine.Combined 1H-NMR and 1H-13C HSQC-NMR to improve urinary screening in autism spectrum disorders.Omics to Explore Amyotrophic Lateral Sclerosis Evolution: the Central Role of Arginine and Proline Metabolism.Medium-Chain Fatty Acids, Beta-Hydroxybutyric Acid and Genetic Modulation of the Carnitine Shuttle Are Protective in a Drosophila Model of ALS Based on TDP-43.NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendationsAmyotrophic Lateral Sclerosis and Frontotemporal DegenerationMulticentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosisTHEME 10IN VITROEXPERIMENTAL MODELS
P2860
Q21183970-F40B23F4-F7E0-4F9C-8F06-9639B4D0F5E3Q26851303-62331D59-C2E6-4F90-B0ED-5275BD65D678Q26992344-94F0BF7D-418A-44C6-B8B6-5335FAD0052EQ28482111-6347C4E3-998F-4FF4-BA45-CA8D85D802F4Q28483618-F9D1C805-B33B-4E8C-AF73-E9B748BAFEB0Q31146776-DCDBFB43-635E-4108-BAE8-7C1BFD0D79F6Q33601031-2D502331-B215-4CD7-9E1E-335288595F42Q33869419-1FDF8A51-4AE9-4CE1-A512-161C6D1FF3F7Q34344992-0C80D046-7E9C-4D38-95D8-E77D9012ABEBQ35008605-7201A68A-5181-4AA7-9CE0-E7EEA98518BBQ35555633-6B4249C0-E5A5-4698-BBCD-6620E10A327CQ36482355-AFFA96E7-C6B8-4F19-BCCB-0E96957B6FB9Q36775915-C6BFD07A-DDF8-43F0-8460-5C2C4127AB5AQ36845593-7EACE179-585F-4FD2-A686-563EB307ACE3Q37338124-AC9FA5FB-F367-4697-BEDC-F9B9374A0B15Q37585552-9097BCF6-44EA-40D1-97C8-B1999C6D66CBQ37594297-5862E84F-D440-462B-8C1D-4A1825FB01DEQ38110171-69E70DE6-1D69-4504-9E5E-6E3DA87B95DCQ38119451-C9409869-70CB-447E-B0EF-A82D562E4614Q38160415-B6B81CBD-4E5A-4743-8187-F5CB5CE56B82Q38272668-DDDFF1D6-6BE2-4FE4-81C6-B1107AF6E1B5Q38575783-6C0988D3-77B7-4319-AC3B-BF669329CAF6Q38715322-19AD81B9-672C-4FC7-9D10-3E7B7D8F754AQ38811833-71C8B9C0-7FFA-41EA-8F59-FC4219750D1BQ39250013-D29084CD-DE78-4639-9CEF-3E5FE28B620EQ39400501-6FF84553-6BA7-4907-94A4-9D20DE35EA8AQ39682976-DCD410DA-3511-48D6-BEC3-30A15A8EDF16Q40385384-BDE235E0-8F31-4C19-99B3-EECB14316F9CQ41472087-EBDF54A2-A362-4018-9C05-51D48753DE94Q42175283-89D85242-59D4-4939-BDA0-736F735E7B66Q46566031-AB07D071-7FAC-489D-ABEC-D16DDD333864Q49334640-CC606C40-3A04-4551-B304-ADBD0EF22708Q50090010-B48160C8-54A6-44FE-B8F9-10D0077DFFF1Q50306889-57AE3697-35F3-48DF-997D-7A6EDD9C6D36Q51825896-C74F54FE-5506-4C3A-A0CC-887D12760BC9Q55237897-8481C5E4-F88E-4F79-901C-C36217DB1535Q57016043-CE281C87-7A9F-4B7A-A692-FBD66B516AD4Q58125262-C7E89D73-F5BE-4A83-8F23-C11EA44F7F25Q58181716-92A4B88D-1346-4662-9EB8-24C97B0647FBQ58307052-C643B6FC-60E8-4EB2-B98F-E90563239C3D
P2860
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@ast
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@en
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@nl
type
label
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@ast
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@en
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@nl
prefLabel
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@ast
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@en
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@nl
P2093
P2860
P50
P1433
P1476
1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis
@en
P2093
Caroline Moreau
Clémentine Fournier
Hélène Blasco
Julien Praline
Lydie Nadal-Desbarats
Patrick Vourc'h
Ségolène Veau
P2860
P304
P356
10.1371/JOURNAL.PONE.0013223
P407
P577
2010-10-08T00:00:00Z